Insulet Stock
Insulet Corp.
Company data
- Sector
- Healthcare
- Industry
- Medical - Devices
- Country
- United States
- CEO
- Ashley McEvoy
- Employees
- 5,400
- Market cap
- $9.8 B
- IPO
- 15/05/2007
Insulet Corp. is a healthcare company operating in the medical devices industry, headquartered in Acton, US. Founded in 2000, the corporation develops, manufactures, and sells insulin delivery systems for individuals with insulin-dependent diabetes across the United States and international markets. The company's…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Insulet stock: price history
1D
+1.7%
1W
+4.3%
1M
+0.4%
6M
-30.7%
YTD
-50.4%
1Y
-55.4%
2Y
-38.8%
5Y
-53.0%
10Y
+255.2%
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~47% stronger price swings than usual
Ask the agents about Insulet
Analyst assessment of Insulet
PRICE TARGET LOW
US$144.00
CONSENSUS
US$182.78
MEDIAN
US$179.50
PRICE TARGET HIGH
US$235.00
0
STRONG BUY
28
BUY
19
HOLD
3
SELL
0
STRONG SELL
50
TOTAL · Buy
As of: 12/10/2026
Insulet stock metrics
P/E
26.32
P/B
6.88
EV/EBITDA
15.51
RETURN ON EQUITY
6.7%
NET MARGIN
11.8%
DEBT/EQUITY
0.67
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
99.6%
FLOAT SHARES
69,052,024
AVG. DAILY VOLUME (30D)
1,660,213
Insider transactions (SEC)
Pease Flavia
MAZELSKY JONATHAN JAY
Huffines Robert Luther
McEvoy Ashley
Davis Lisa Blair
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: +1.7%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Insulet stock
What does Insulet do?
Insulet Corp. is a company in the Healthcare sector, Medical - Devices industry, headquartered in United States.
The CEO is Ashley McEvoy, the company employs around 5,400 people.
The IPO was on 15/05/2007; the stock trades on NASDAQ under the ticker PODD.
What do analysts say about Insulet stock?
50 analysts rate the stock, the consensus is Buy (as of 12/10/2026).
The average price target is US$182.78, ranging from US$144.00 to US$235.00, with a median of US$179.50.
This is an external assessment, not a statement by Market Jury.
When does Insulet report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly 47% stronger than usual.
Does Insulet pay a dividend?
No, Insulet currently does not pay a dividend.
Which stocks are comparable to Insulet?
Comparable stocks include Abbott Laboratories, Stryker, Boston Scientific, Edwards Lifesciences, DexCom, GE HealthCare Technologies, Zimmer Biomet Holdings and Align Technology.
How can I get Insulet stock analyzed?
Clicking "Analyze stock" lets five strategies assess Insulet against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.